Sanofi India Limited is amongst the leading multinational companies in the Indian Pharmaceutical Market. It offers a wide array of medicines for therapy areas such as Diabetes, Cardiology, Thrombosis, Central Nervous System and Anti-histamines.
Financial Results:
Sanofi India Ltd reported Revenues for Q3FY25 of ₹515.00 Crores up from ₹469.00 Crore year on year, a rise of 9.81%.
Total Expenses for Q3FY25 of ₹407.00 Crores up from ₹379.00 Crores year on year, a rise of 7.39%.
Consolidated Net Profit of ₹91.00 Crores down 34.06% from ₹138.00 Crores in the same quarter of the previous year.
The Earnings per Share is ₹39.70, down 33.69% from ₹59.87 in the same quarter of the previous year.
![](data:image/svg+xml;charset=utf-8,<svg height="781px" width="640px" xmlns="http://www.w3.org/2000/svg" version="1.1"/>)
